AVITA Medical, Inc (AVH) Fair Value & Analysis
Healthcare · AU · Market cap A$190M
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 29 days ago
Share price +32.7% over the past month.
Price vs Fair Value (12 months)
12‑month range A$1.01 – A$1.93 · fair‑value band A$1.07 – A$1.79 · the A$1.46 price screens above the A$1.44 fair value. As of Jun 23, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
AVITA Medical, Inc (AVH) currently trades at A$1.46, while our model-based Fair Value estimate is A$1.44, implying the stock looks roughly 1.6% fairly valued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, AVITA Medical, Inc generated revenue of A$72.3M at a net margin of -62.7%. Revenue grew 4.0% year over year. Net debt stands at A$38.0M. Fundamentals as of Jun 23, 2026
Our scenario range runs from A$1.07 (bear case) to A$1.79 (bull case); at A$1.46, the current price sits within that range. The share trades about 26% below its 52-week high and 46% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -24% fair-value upside, at -2%, AVH screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
AVITA Medical, Inc reported revenue of A$74.1M in FY2025 versus A$14.3M in FY2021, a compound +51.0%/yr. Reported net income was −A$50.3M in FY2025.
Is AVH fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $89.17 | $70.59 | -21% |
| Stryker Corporation SYK | $308.84 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$211.05 | R$29.52 | -86% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €75.90 | €37.29 | -51% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| STERIS plc S1TE34 | R$52.14 | R$39.50 | -24% |
| Zimmer Biomet Holdings Z1BH34 | R$116.16 | R$85.57 | -26% |
| Shanghai United Imaging Healthcare Co 688271 | ¥104.19 | ¥45.36 | -56% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is AVITA Medical, Inc (AVH) undervalued?
What is the fair value of AVH?
What is the quality score of AVH?
What is the revenue of AVITA Medical, Inc (AVH)?
What is the net profit margin of AVH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full AVITA Medical, Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.